bioRxiv
July 23, 2026
W. J. Tyler, E. Sellers, M. McDonnell
preprint
Repeated low-dose psilocybin is being developed as a scalable outpatient treatment for mood and anxiety disorders, but chronic exposure raises concern because psilocin binds the cardiac serotonin 5-HT2B receptor, whose sustained agonism causes drug-induced valvular heart disease (VHD). We evaluated this risk using an exposure–response model that incorporates functional efficacy and exposure...
medRxiv
July 19, 2026
Naama Levy‐Cooperman, Edward M. Sellers, Paul Glue et al.
Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10-25 mg) require in-clinic supervision, which limits scalability. Whether the therapeutically relevant pharmacology of psilocybin can be separated from its hallucinogenic activity remains unresolved. To address this gap, we conducted a Phase...
Preprints.org
November 4, 2025
William J. Tyler
preprint
Religious and spiritual (R/S) practices and experiences invoke measurable neurocognitive processes that enhance resilience and recovery from affective disorders. Converging evidence from functional neuroanatomy and network studies demonstrate R/S practices recruit brain networks that regulate self-referential processing, salience attribution, executive control, reward, and social bonding....
medRxiv
November 27, 2020
Maria E Fini, William J. Tyler
5 citations
preprint
ABSTRACT The dorsal anterior cingulate cortex (dACC) operates as an integrator of bottom-up and top-down signals and is implicated in both cognitive control and emotional processing. The dACC is believed to be causally involved in switching between attention networks, and previous work has linked it to cognitive performance, concentration, relaxation, and emotional distraction. The present...